UiPath's recent Peak acquisition is likely to drive renewed growth opportunity. Read why we are reiterating our Buy rating ...

Morgan Stanley analyst Sanjit Singh maintained a Hold rating on UiPath (PATH – Research Report) today and set a price target of $12.00.Stay ...

Visa also continually rolls out new products that deliver benefits to customers, vendors, and merchants. Earlier in April, ...

Mizuho lowered the firm’s price target on UiPath (PATH) to $11 from $12 and keeps a Neutral rating on the shares as part of a Q1 preview for ...

UiPath (PATH) closed the most recent trading day at $10.71, moving -1.47% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.79%. Elsewhere, the Dow ...

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

UiPath (PATH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

As of the market close on April 9, there's one top AI stock that's trading at a price-to-earnings (P/E) ratio of 19. That's ...

Despite a 20% stock decline, we maintain a bullish view on UiPath due to its strategic pivot to Agentic AI and strong ...

Learn more about whether CleanSpark, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Amidst this news, share prices of the companies ... of slowing revenue growth. UiPath delivered the weakest performance ...